>北美 IgA 肾病市场，按疾病类型（原发性 IgA 肾病和继发性 IgA 肾病）、症状（血尿、蛋白尿、水肿等）、类型（诊断和治疗）、人群类型（儿科和成人）、给药途径（口服、肠外和其他）、最终用户（医院、诊所、家庭医疗保健和其他）、分销渠道（直接招标、医院药房、零售药房、网上药房和其他）、国家（美国、加拿大、墨西哥）划分，行业趋势和预测到 2028 年。
市场分析和见解：北美 IgA 肾病市场
北美 IgA 肾病市场预计将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2021 年至 2028 年的预测期内，市场以 19.7% 的复合年增长率增长，预计将从 2020 年的 1.2649 亿美元增至 2028 年的 4.514 亿美元。IgA 肾病药物发现的增加是预测期内推动市场需求的主要驱动力。IgA 肾病疾病的增加增加了疾病负担，增加了对诊断和治疗产品的需求，从而推动了北美 IgA 肾病市场的增长。
IgA 肾病又称伯杰氏病，是一种因肾脏中 IgA 沉积物堆积而引起的肾脏疾病，可导致肾脏组织发炎和损伤。IgA 等抗体是由免疫系统产生的蛋白质，可保护身体免受细菌和病毒等外来物质的侵害。这种疾病的并发症是 ESKD，需要透析治疗。
针对 IgA 肾病的药物管线不断增加，使潜在候选药物能够显示出对 IgA 肾病治疗的疗效，从而成为 IgA 肾病市场的驱动力。如果没有报销，治疗 IgA 肾病的费用会增加患者的负担，从而限制 IgA 肾病市场的增长。市场参与者在药物开发方面的合作增加了存在感和创新性，从而为 IgA 肾病市场的增长提供了机会。与治疗 IgA 肾病相关的副作用以及 COVID-19 对免疫抑制药物市场的影响对 IgA 肾病市场的增长构成了挑战。
北美 IgA 肾病市场报告提供了市场份额、新发展和产品线分析的详细信息，国内和本地市场参与者的影响，分析了新兴收入领域、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和 IgA 肾病市场情景，请联系 Data Bridge Market Research 获取分析师简报；我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标。
北美 IgA 肾病市场范围和市场规模
北美 IgA 肾病市场根据疾病类型、症状、类型、人群类型、给药途径、最终用户和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据疾病类型，北美 IgA 肾病市场分为原发性 IgA 肾病和继发性 IgA 肾病。2021 年，原发性 IgA 肾病细分市场预计将占据市场主导地位，因为原发性 IgA 肾病的发病率较高，并且可以通过血液或尿液检查轻松诊断。
- 根据症状，北美 IgA 肾病市场分为血尿、蛋白尿、水肿等。2021 年，血尿部分预计将占据市场主导地位，因为它是临床检查中最常见和最常用的参数，通过尿液中的血液量检测可显示肾脏疾病的发生。
- 根据类型，北美 IgA 肾病市场分为诊断和治疗。2021 年，诊断部分预计将占据市场主导地位，因为在进行治疗之前，必须对 IgA 肾病进行适当的检测和追踪。只有通过血液和尿液检测等初步检测以及肾活检的确认检测才有可能，这是该部分的主要因素。
- 根据人口类型，北美 IgA 肾病市场分为儿科和成人。2021 年，成人市场预计将出现显著增长，因为研究表明该疾病与衰老有关。
- 根据给药途径，北美 IgA 肾病市场分为口服、肠外和其他。2021 年，口服药物市场预计将占据市场主导地位，因为州际贸易中提供种类繁多的口服产品组合，从而增加了该市场的市场份额。
- 根据最终用户，北美 IgA 肾病市场分为医院、诊所、家庭医疗保健和其他。2021 年，医院部门预计将凭借其强大的财务结构占据市场主导地位。
- 根据分销渠道，北美 IgA 肾病市场细分为直接招标、医院药房、零售药房、网上药房等。2021 年，直接招标部分加速收入增长并提供税收优惠。直接招标部分在过去几年一直蓬勃发展，从今以后，肯定表明市场将进一步增长。
北美 IgA 肾病市场国家级分析
北美 IgA 肾病市场根据疾病类型、症状类型、人群类型、给药途径、最终用户和分销渠道进行细分。
北美 IgA 肾病市场报告涵盖的国家包括美国、加拿大和墨西哥。
由于北美地区研究人员和科学家对 IgA 肾病的需求不断增加，预计北美将主导市场。由于该地区主要市场参与者的存在不断增加，美国正在主导市场并引领北美市场的增长。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、销售渠道的影响。
收购和合并不断增加为北美 IgA 肾病市场参与者创造新机遇
北美 IgA 肾病市场还为您提供了每个国家增长的详细市场分析。此外，它还提供有关主要市场参与者和初创公司之间的收购和协议的数据。此外，研发活动对北美 IgA 肾病市场增长速度的影响越来越大。数据适用于 2010 年至 2019 年的历史时期。
竞争格局和北美 IgA 肾病市场份额分析
北美 IgA 肾病市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用主导地位和技术生命线曲线。以上提供的数据点仅与公司对北美 IgA 肾病市场的关注有关。
北美 IgA 肾病报告中涉及的主要参与者包括阿斯利康、诺华公司、辉瑞公司、Zydus Cadila、Teva Pharmaceutical USA, Inc.（Teva Pharmaceuticals Industries Ltd. 的子公司）、Hikma Pharmaceuticals PLC、LUPIN、Accord Health、Viatris Inc.、Seimens Healthcare GmBH（Seimens Healthineers AG 的子公司）、ARAKAY USA, Inc.、默克夏普和 Dohme.（默克公司的子公司）、Strides Pharma Science Limited 和 Apotex Inc.，以及其他国内和全球参与者。DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。
全球各地的公司也签订了许多合同和协议，加速了IgA肾病市场的发展。
例如，
- 2017 年 3 月，Apotex Inc. 宣布已投资 1.84 亿美元扩大美国制造业务。这是该公司在美国最大的一笔投资。这增加了公司的制造能力，以满足对产品的需求
市场参与者的合作、合资等策略提升了公司在北美 IgA 肾病市场的印象，这也有利于该组织提高其 IgA 肾病销售增长。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA IGA NEPHROPATHY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 NORTH AMERICA IGA NEPHROPATHY MARKET: COMPETITIVE ENVIRONMENT
6 NORTH AMERICA IGA NEPHROPATHY MARKET: REGULATIONS
6.1 THE U.S. REGULATORY FRAMEWORK FOR IGA NEPHROPATHY
7 CURRENT STUDIES ON ARCHAEOSOMES
8 EPIDEMIOLOGY
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISE IN IGA NEPHROPATHY DISORDER
9.1.2 INCREASING IGA TARGETED PIPELINE DRUGS
9.1.3 INCREASE RESEARCH & DEVELOPMENT INVESTMENT FOR DRUG DISCOVERY
9.1.4 REIMBURSEMENT PROVIDED FOR KIDNEY DISORDERS
9.1.5 UPCOMING AND RECENT APPROVAL FOR IGA NEPHROPATHY TREATMENT
9.2 RESTRAINTS
9.2.1 HIGH COST OF IGA NEPHROPATHY TREATMENT
9.2.2 DELAYED DIAGNOSIS OF IGA DISORDERS
9.2.3 INABILITY TO STOP PROGRESSION OF IGA NEPHROPATHY BY CURRENT TREATMENT
9.3 OPPORTUNITIES
9.3.1 COLLABORATION OF MARKET PLAYERS FOR DRUG DEVELOPMENT
9.3.2 GOVERNMENT FUNDING FOR RESEARCH PURPOSE
9.3.3 INCREASE TREND FOR NOVEL DIAGNOSIS PROCEDURE
9.4 CHALLENGES
9.4.1 LOW AWARENESS REGARDING KIDNEY DISEASE
9.4.2 SIDE EFFECT IGA NEPHROPATHY TREATMENT DRUGS
10 IMPACT OF COVID 19 ON THE NORTH AMERICA IGA NEPHROPATHY MARKET
10.1 IMPACT ON PRICE
10.2 IMPACT OF DEMAND:
10.3 IMPACT ON SUPPLY CHAIN:
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS:
10.5 CONCLUSION:
11 NORTH AMERICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE
11.1 OVERVIEW
11.2 PRIMARY IGA NEPHROPATHY
11.3 SECONDARY IGA NEPHROPATHY
12 NORTH AMERICA IGA NEPHROPATHY MARKET, BY SYMPTOMS
12.1 OVERVIEW
12.2 HEMATURIA
12.3 PROTEINURIA
12.4 EDEMA
12.5 OTHERS
13 NORTH AMERICA IGA NEPHROPATHY MARKET, BY TYPE
13.1 OVERVIEW
13.2 DIAGNOSIS
13.2.1 URINE TEST
13.2.1.1 URINE ALBUMIN-TO-CREATININE RATIO
13.2.1.2 DIPSTICK TEST FOR ALBUMIN AND BLOOD
13.2.2 BLOOD TEST
13.2.3 IOTHALAMATE CLEARANCE TEST
13.2.4 KIDNEY BIOPSY
13.2.5 OTHERS
13.3 TREATMENT
13.3.1 BLOOD PRESSURE LOWERING AGENTS
13.3.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
13.3.1.1.1 LISINOPRIL
13.3.1.1.2 ENALAPRIL
13.3.1.1.3 RAMIPRIL
13.3.1.1.4 BENAZEPRIL
13.3.1.2 OTHERS
13.3.2 ANGIOTENSIN RECEPTOR BLOCKERS (ARBS)
13.3.2.1 LOSARTAN
13.3.2.2 VALSARTAN
13.3.2.3 IRBESARTAN
13.3.2.4 OTHERS
13.3.3 IMMUNOSUPPRESANT
13.3.3.1 CYCLOPHOSPHAMIDE
13.3.3.2 AZATHIOPRINE
13.3.3.3 CORTICOSTEROIDS
13.3.3.3.1 METHYLPREDNISONE
13.3.3.3.2 PREDNISOLONE
13.3.3.3.3 OTHERS
13.3.4 DIURETICS
13.3.4.1 FUROSEMIDE
13.3.4.2 TORSEMIDE
13.3.5 BUMETANIDE
13.3.6 OTHERS
13.3.7 LOWER BLOOD CHOLESTEROL
13.3.7.1 ATROVASTATIN
13.3.7.2 SIMVASTATIN
13.3.7.3 ROSUVASTATIN
13.3.7.4 FLUVASTATIN
13.3.7.5 PRAVASTATIN
13.3.7.6 OTHERS
13.3.8 SUPPLEMENTS
13.3.8.1 OMEGA-3-FATTY ACIDS
13.3.8.2 VITAMIN E
13.3.8.3 OTHERS
13.3.9 OTHERS
14 NORTH AMERICA IGA NEPHROPATHY MARKET, BY POPULATION TYPE
14.1 OVERVIEW
14.2 ADULTS
14.3 PEDIATRICS
15 NORTH AMERICA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLETS/PILLS
15.2.2 CAPSULES
15.2.3 OTHERS
15.3 PARENTERAL
15.3.1 INTRAVENOUS
15.3.2 INTRAMUSCULAR
15.3.3 OTHERS
15.4 OTHERS
16 NORTH AMERICA IGA NEPHROPATHY MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 CLINICS
16.4 HOME HEALTHCARE
16.5 OTHERS
17 NORTH AMERICA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 HOSPITAL PHARMACY
17.3 RETAIL PHARMACY
17.4 ONLINE PHARMACY
17.5 DIRECT TENDER
17.6 OTHERS
18 NORTH AMERICA IGA NEPHROPATHY MARKET, BY COUNTRY
18.1 NORTH-AMERICA
18.1.1 U.S.
18.1.2 CANADA
18.1.3 MEXICO
19 NORTH AMERICA IGA NEPHROPATHY MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
20 SWOT
21 COMPANY PROFILES
21.1 VIATRIS INC.
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 TEVA PHARMACEUTICAL USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE FINANCIALS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 LUPIN
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE FINANCIALS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENTS
21.4 ACCORD HEALTHCARE
21.4.1 COMPANY SNAPSHOT
21.4.2 COMPANY SHARE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENTS
21.5 ASTRAZENECA
21.5.1 COMPANY SNAPSHOT
21.5.2 RECENT FINANCIALS
21.5.3 PRODUCT PORTFOLIO
21.5.4 RECENT DEVELOPMENTS
21.6 PFIZER INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE FINANCIALS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENTS
21.7 ZYDUS CADILLA
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE FINANCIALS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENTS
21.8 NOVARTIS AG
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE FINANCIALS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENTS
21.9 ALEMBIC PHARMACEUTICALS LIMITED
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENTS
21.1 STRIDES PHARMA SCIENCE LIMITED
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE FINANCIALS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENTS
21.11 SIEMENS HEALTHCARE GMBH (A SUBSIDIARY OF SIEMENS HEALTHINEERS AG)
21.11.1 COMPANY SNAPSHOT
21.11.2 REVENUE FINANCIALS
21.11.3 PRODUCT PORTFOLIO
21.11.4 RECENT DEVELOPMENTS
21.12 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENTS
21.13 HIKMA PHARMACEUTICALS PLC
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENTS
21.14 SUN PHARMACEUTICAL INDUSTRIES LTD.
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE FINANCIALS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 APOTEX INC.
21.15.1 COMPANY SNAPSHOT
21.15.2 PRODUCT PORTFOLIO
21.15.3 RECENT DEVELOPMENTS
21.16 ARKRAY USA, INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 PRODUCT PORTFOLIO
21.16.3 RECENT DEVELOPMENTS
21.17 CALIDITAS THERAPEUTICS AB
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE FINANCIALS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENTS
21.18 CAREDX, INC.
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENTS
21.19 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE FINANCIALS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT DEVELOPMENTS
21.2 OMEROS CORPORATION
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
22 QUESTIONNAIRE
23 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 2 NORTH AMERICA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 3 NORTH AMERICA IGA NEPHROPATHY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA URINE TEST IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA TREATMENT BY IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 21 NORTH-AMERICA IGA NEPHROPATHY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 22 U.S. IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 23 U.S. IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 24 U.S. IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 25 U.S. DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 26 U.S. DIAGNOSIS BY URINE IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 27 U.S. TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 U.S. TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 29 U.S. TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 30 U.S. TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 31 U.S. TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 32 U.S. TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 33 U.S. IGA TREATMENT BY DIURETICS IN NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 34 U.S. TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 35 U.S. TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 36 U.S. IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 37 U.S. IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 38 U.S. ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 39 U.S. PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 40 U.S. IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 U.S. IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 42 CANADA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 43 CANADA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 44 CANADA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 45 CANADA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 46 CANADA DIAGNOSIS BY URINE IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 CANADA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 CANADA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 CANADA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 CANADA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 CANADA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 CANADA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 53 CANADA TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 CANADA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 55 CANADA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 56 CANADA IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 57 CANADA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 58 CANADA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 59 CANADA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 60 CANADA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 61 CANADA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 62 MEXICO IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 63 MEXICO IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 64 MEXICO IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 MEXICO DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 MEXICO DIAGNOSIS BY URINE IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 MEXICO TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 MEXICO TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 MEXICO TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 70 MEXICO TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 71 MEXICO TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 72 MEXICO TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 73 MEXICO TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 74 MEXICO TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 MEXICO TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 MEXICO IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 77 MEXICO IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 78 MEXICO ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 79 MEXICO PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 80 MEXICO IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 81 MEXICO IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA IGA NEPHROPATHY MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA IGA NEPHROPATHY MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA IGA NEPHROPATHY MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA IGA NEPHROPATHY MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA IGA NEPHROPATHY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA IGA NEPHROPATHY MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA IGA NEPHROPATHY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA IGA NEPHROPATHY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA IGA NEPHROPATHY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA IGA NEPHROPATHY MARKET: MARKET END USER COVERAGE GRID
FIGURE 11 NORTH AMERICA IGA NEPHROPATHY MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA RISE IN IGA NEPHROPATHY DISORDER IS DRIVING THE NORTH AMERICA IGA NEPHROPATHY MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 PRIMARY IGA NEPHROPATHY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA IGA NEPHROPATHY MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA IGA NEPHROPATHY MARKET
FIGURE 15 IGA NEPHROPATHY BIOPSIES IN DIFFERENT REGIONS
FIGURE 16 NORTH AMERICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, 2020
FIGURE 17 NORTH AMERICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)
FIGURE 18 NORTH AMERICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, CAGR (2020-2028)
FIGURE 19 NORTH AMERICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, 2020
FIGURE 21 NORTH AMERICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, 2020-2028 (USD MILLION)
FIGURE 22 NORTH AMERICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, CAGR (2020-2028)
FIGURE 23 NORTH AMERICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, LIFELINE CURVE
FIGURE 24 NORTH AMERICA IGA NEPHROPATHY MARKET: BY TYPE, 2020
FIGURE 25 NORTH AMERICA IGA NEPHROPATHY MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 26 NORTH AMERICA IGA NEPHROPATHY MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 27 NORTH AMERICA IGA NEPHROPATHY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 28 NORTH AMERICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, 2020
FIGURE 29 NORTH AMERICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)
FIGURE 30 NORTH AMERICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, CAGR (2020-2028)
FIGURE 31 NORTH AMERICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 32 NORTH AMERICA IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 33 NORTH AMERICA IGA NEPHROPATHY MARKET: BY ROUTE OFADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 34 NORTH AMERICA IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 35 NORTH AMERICA IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 NORTH AMERICA IGA NEPHROPATHY MARKET: BY END USER, 2020
FIGURE 37 NORTH AMERICA IGA NEPHROPATHY MARKET: BY END USER , 2020-2028 (USD MILLION)
FIGURE 38 NORTH AMERICA IGA NEPHROPATHY MARKET: BY END USER, CAGR (2020-2028)
FIGURE 39 NORTH AMERICA IGA NEPHROPATHY MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 NORTH AMERICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 41 NORTH AMERICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 42 NORTH AMERICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 43 NORTH AMERICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 NORTH-AMERICA IGA NEPHROPATHY MARKET: SNAPSHOT (2020)
FIGURE 45 NORTH-AMERICA IGA NEPHROPATHY MARKET: BY COUNTRY (2020)
FIGURE 46 NORTH-AMERICA IGA NEPHROPATHY MARKET: BY COUNTRY (2021 & 2028)
FIGURE 47 NORTH-AMERICA IGA NEPHROPATHY MARKET: BY COUNTRY (2020 & 2028)
FIGURE 48 NORTH-AMERICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 49 North America IgA Nephropathy Market: company share 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
